Oncology specialists are increasingly prioritizing tivozanib monotherapy for patients with metastatic clear-cell renal cell carcinoma (ccRCC) following progression on initial immunotherapy.
Recent clinical discussions and evidence reviews suggest that while combination therapies offer high efficacy, the manageable toxicity profile of tivozanib makes it a preferred second-line choice for many clinicians.
The challenge of managing ccRCC after first-line failure remains a complex clinical puzzle. As new immunotherapy combinations enter the frontline setting, the available “salvage” or second-line options must be re-evaluated to balance survival benefits against the burden of side effects. According to a report by Targeted Onc, recent expert polling and trial data are reshaping how physicians sequence these powerful drugs.
Clinical Implications for Second-Line ccRCC Care
- Tivozanib is a leading contender: Many doctors prefer tivozanib alone because it offers a strong balance of disease control and manageable side effects compared to more aggressive combinations.
- Combination therapy carries higher risks: While drugs like lenvatinib plus everolimus may show high response rates, they often come with a greater risk of severe adverse events.
- Immunotherapy rechallenge is losing favor: Data suggests that trying to use the same type of immunotherapy a patient has already failed against may not provide additional benefits.
Expert Consensus Shifts Toward Tivozanib
Targeted Onc reported that the initial poll showed an even split among lenvatinib plus everolimus, lenvatinib plus belzutifan, and tivozanib.
Tivozanib emerged as the clear favorite, selected by 58.3% of the 12 participants. Furthermore, 83.3% of the experts indicated they would likely utilize tivozanib in a similar second-line clinical setting.
This shift was driven by the need to balance overall survival (OS) with the patient’s quality of life. Christopher Wee, MD, of Cleveland Clinic Taussig Cancer Center, noted that while maximizing survival is the goal, clinicians must also aim for “durability of response in the second line” to ensure the treatment provides meaningful “mileage” for the patient.
Evidence From Key Clinical Trials
The preference for tivozanib is grounded in several high-impact phase 3 trials. The TIVO-3 trial demonstrated that tivozanib improved median progression-free survival (PFS)—the length of time a patient lives with stable disease—compared to sorafenib. While final OS results did not show a difference, the PFS advantage was clear.
The TiNivo-2 trial provided further guidance regarding immunotherapy. When evaluating tivozanib alone versus adding nivolumab (an immune checkpoint inhibitor) after prior ICI therapy, the addition of nivolumab did not improve outcomes.
In fact, the median PFS was higher with tivozanib monotherapy at 9.2 months compared to 5.9 months with the combination. This finding led Lingbin Meng, MD, of The Ohio State University Comprehensive Cancer Center, to express increased confidence in using tivozanib alone in the second-line setting.
Conversely, the CONTACT-03 trial provided evidence against “rechallenging” patients with similar immunotherapy classes. The trial found that adding atezolizumab to cabozantinib did not improve PFS or OS compared to cabozantinib alone, while simultaneously increasing toxicity. This aligns with the decision by poll participants to avoid ICI rechallenge entirely.
Compare Efficacy and Safety of Treatment Regimens
| Treatment Regimen | Primary Benefit (Median PFS) | Key Clinical Consideration |
|---|---|---|
| Lenvatinib + Everolimus | 15.7 months (Phase 2) | Higher risk of severe adverse events |
| Tivozanib Monotherapy | 9.2 months (TiNivo-2 subgroup) | Manageable toxicity profile |
| Cabozantinib Monotherapy | 10.2 months (LenCabo) | Standard of care in various settings |
The Role of Belzutifan and Combination Risks
Belzutifan represents a newer mechanism of action, targeting hypoxia-inducible factor 2-alpha (HIF-2α). While the LITESPARK-005 trial showed that belzutifan had a higher objective response rate (the percentage of patients whose tumor shrinks) than everolimus, the OS data remained non-significant at the second interim analysis. Clinicians must also monitor for specific side effects, such as anemia and hypoxia (low oxygen levels), associated with belzutifan.
A network meta-analysis published by Elsevier corroborated the high efficacy of the lenvatinib plus everolimus combination, ranking it first for OS and PFS. However, the analysis also highlighted a significant trade-off: this combination was associated with a much higher likelihood of severe adverse events (SAEs) compared to other options. This explains why, despite its potency, it was only selected by 25% of the experts in the Targeted Onc poll.
The complexity of these decisions is further compounded by the expanding list of first-line treatments. As noted by Elsevier, the availability of newer front-line immune-checkpoint inhibitor and tyrosine-kinase inhibitor (TKI) combinations will continue to influence how doctors sequence these second-line therapies.
Contraindications & When to Consult a Doctor
Patients undergoing TKI or immunotherapy combinations must be closely monitored for systemic toxicities.
Treatment decisions must be individualized based on a patient’s ECOG performance status—a scale used to assess how a patient’s disease affects their daily living abilities—and their specific comorbidity profile.
References
- The Lancet Oncology (TIVO-3 Trial)
- The Lancet (TiNivo-2 Trial)
- Annals of Oncology (LenCabo Trial)
- ScienceDirect/Elsevier (Network Meta-analysis of 2L ccRCC)
